nemonoxacin nemonoxacin nemonoxacin is a non-fluorinated quinolone antibiotic undergoing clinical trials. it has the same mechanism of action as fluouroquinolones; it inhibits dna gyrase, preventing dna synthesis, gene duplication, and cell division. at the end of 2016, it had reached market in taiwan, russia, the commonwealth independent states, turkey, mainland china, and latin america under the brand name taigexyn. nemonoxacin has completed phase 2 trials in the us and has moved on to phase 3 trials. the u.s. food and drug administration (fda) has granted nemonoxacin qualified infectious disease product (qidp) and fast track designations for community-acquired bacterial pneumonia (cap) and acute bacterial skin and skin-structure infections (absssi). nemonoxacin names preferred iupac name 7--1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid identifiers cas number 378746-64-6 n 3d model (jsmol) interactive image chebi chebi:136053 chembl chembl1213456 chemspider 10166207 drugbank db06600 iuphar/bps 10836 pubchem cid 11993740 unii p94l0pvo94 comptox dashboard (epa) dtxsid10958907 inchi inchi=1s/c20h25n3o4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13h,3-4,7-9,21h2,1-2h3,(h,25,26)/t11-,12-/m0/s1key: avpqpgflvztjor-ryudhwbxsa-ninchi=1/c20h25n3o4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13h,3-4,7-9,21h2,1-2h3,(h,25,26)/t11-,12-/m0/s1key: avpqpgflvztjor-ryudhwbxbz smiles c1c(n)cn(c1)c2ccc3c(c2oc)n(c4cc4)cc(c3=o)c(=o)o properties chemical formula c20h25n3o4 molar mass 371.437 g·mol−1 pharmacology atc code j01mb08 (who) except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references nemonoxacin has a broad spectrum of activity against gram-positive, gram-negative, and atypical pathogens, including activity against methicillin-resistant staphylococcus aureus (mrsa) (mic90 1 g/ml) and vancomycin-resistant pathogens. however, it was less active against gram-negative pathogens such as escherichia coli, proteus mirabilis, and pseudomonas aeruginosa, with mic90 values of 32, 16, and 32 g/ml, respectively. the new drug also is effective against c.difficile isolates that are resistant to other quinolones, and is more potent than levofloxacin or moxifloxacin.